Understanding heterogeneous TIMEs in ALK rearrangement-positive LCNEC may offer crucial information to optimize the use of immunotherapy, radiotherapy and chemotherapy and may be instructive to discover novel therapeutic approaches for improving the actual cure rate of advanced lung cancer [1]. This evidence concerns the gene ALK and lung cancer.